Naldemedine Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 0.2 mg
Reference Brands: Symproic (USA/EU)
Category:
Gastrointestinal Drugs
Naldemedine is available in Tablets
and strengths such as 0.2 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Naldemedine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Naldemedine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Naldemedine is a peripherally acting μ-opioid receptor antagonist used for the treatment of opioid-induced constipation in adults. It is specifically indicated in the United States for patients with chronic non-cancer pain, including pain related to prior cancer or its treatment, and in the European Union for adults who have previously used a laxative for opioid-induced constipation. Naldemedine works by blocking opioid receptors in the gastrointestinal tract, which helps restore normal bowel function without interfering with the central pain-relieving effects of opioids.
The medication has been shown in clinical studies to be effective in increasing bowel movement frequency and improving related symptoms, with most side effects being mild to moderate and primarily gastrointestinal in nature. Central opioid withdrawal symptoms or effects on analgesia are rare. Naldemedine is marketed under the brand name Symproic in the US and Rizmoic in the EU, and was developed by Shionogi. Its targeted mechanism of action allows patients to maintain opioid pain therapy while effectively managing constipation, improving overall comfort and quality of life.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing